December 19, 2025 | Salt Lake City, Utah — Wasatch BioLabs announced a co-marketing agreement with Agilent Technologies to accelerate adoption of native-read targeted sequencing using Wasatch’s Direct Targeted Methylation Sequencing (dTMS) platform. The collaboration integrates Agilent’s SureSelect and Avida enrichment chemistries with Oxford Nanopore–based native-read workflows, expanding access to scalable, targeted multi-omic analysis for RUO and clinical research studies.
Science Significance
Scientifically, the partnership addresses a longstanding limitation in genomics by enabling precise, custom targeting up to 1 Mb while preserving native DNA features, including methylation states and structural variants. By avoiding bisulfite conversion, PCR amplification bias, and off-target sequencing, dTMS captures true biological signals across both large and short genomic regions. This capability is particularly impactful for liquid biopsy, repeat expansion analysis, allelic context resolution, and integrated genetic–epigenetic profiling in a single assay. Early adopters across oncology, neurology, rare disease, and prenatal research demonstrate how native-read targeted sequencing can deliver mechanism-informed insights at scale.
Regulatory Significance
While positioned for research use, the workflow emphasizes consistency, reproducibility, and operational reliability—attributes essential for future clinical translation. The combination of standardized enrichment chemistries and audit-ready laboratory systems supports data generation that aligns with GLP/GCP-supporting environments. By reducing sources of technical bias and preserving native molecular features, the approach strengthens data integrity, a critical consideration for regulatory science, assay validation, and eventual clinical-grade method development.
Business Significance
Advertisement
From a commercial perspective, the co-marketing agreement pairs Agilent’s global reach and trusted enrichment portfolio with Wasatch BioLabs’ specialized long-read service model, lowering adoption barriers for institutions that lack in-house long-read infrastructure. Joint delivery of scientific content, education, and demonstrations through 2027 is designed to scale market awareness and utilization. The service’s early-access availability through Q1 2026 invites partners to shape roadmap enhancements, while the send-out model accelerates turnaround and expands access for biopharma, biotech, and academic teams.
Patients’ Significance
Although patient-facing benefits are indirect at this stage, the technology underpins advances that can improve disease detection, stratification, and monitoring. Enhanced resolution of epigenetic patterns and structural variants informs biomarker discovery and liquid biopsy applications, which can ultimately translate to earlier diagnosis and more precise treatment decisions. As assays mature toward clinical readiness, patients stand to benefit from more accurate, comprehensive genomic insights derived from native DNA.
Policy Significance
The collaboration aligns with policy priorities that encourage innovation in laboratory analytics, reproducibility, and scalable research infrastructure. By emphasizing workflows that minimize bias and preserve biological fidelity, the initiative supports broader goals around data quality and standardization in genomics. Public and private stakeholders increasingly recognize that robust upstream technologies are foundational to effective clinical translation and regulatory confidence.
Together, Wasatch BioLabs and Agilent Technologies are advancing a practical, scalable path for native-read targeted sequencing that bridges innovation and operational rigor. By integrating best-in-class enrichment chemistries with proprietary long-read workflows, the alliance strengthens the analytical backbone needed for high-throughput research today and regulated clinical applications tomorrow. For the cGxP.wire audience, the collaboration exemplifies how technology partnerships can elevate data integrity, reproducibility, and translational readiness across the genomics ecosystem.
Source: Wasatch BioLabs press release
